The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Liraglutide and Renal Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach. Changes in the estimated glomerular filtration rate and albuminuria were also analyzed. RESULTS: A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years. The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven primarily by the new onset of persistent macroalbuminuria, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively). CONCLUSIONS: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The LEADER and REWIND trials also report a greater than 20% reduction in the risk of developing new macroalbuminuria, along with favourable trends in other clinically relevant adverse renal outcomes. 26,27”
The cited source says what the claim attributes to it.
In the citing paper
“Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) have also been shown to improve kidney outcomes (95-100).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1 RAs have also been shown to improve kidney outcomes (104-109).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [106]
In the citing paper
“However, the composite kidney outcomes in these trials were evaluated as secondary outcomes, and the reported effects were largely driven by a lower risk of new-onset macroalbuminuria. 23-25”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [24]
In the citing paper
“Treatment with these drugs is in fact associated with a reduced decline in the estimated glomerular filtration rate (eGFR), as well as with a reduction in urinary albumin excretion and in the incidence rate of de novo albuminuria [28,29].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [28]
In the citing paper
“However, these benefits were driven by a lower risk of persistent macroalbuminuria [6,10,13].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationStevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952
Cited by
Sorted by citations
Items 201–300 of 1,000
Frazier, R., Mehta, R., Cai, X., Lee, J., Napoli, S., Craven, T., Tuazon, J., Safdi, A., Scialla, J., Susztak, K., et al. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2018.09.006 · Cited by 63
Thomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 63
Kramer, H., Boucher, R. E., Leehey, D. J., Fried, L. F., Wei, G., Greene, T., Rosas, S. E., Cooper, R., Cao, G., & Beddhu, S. (2018) · Diabetes Care · doi:10.2337/dc17-1954 · Cited by 63
Harris, S. T., Patorno, E., Zhuo, M., Kim, S. C., & Paik, J. M. (2021) · Diabetes Care · doi:10.2337/dc21-0529 · Cited by 63
Perkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0279 · Cited by 62
Self-citationLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
He, M., Li, Y., Wang, L., Guo, B., Mei, W., Zhu, B., Zhang, J., Ding, Y., Meng, B., Zhang, L., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05197-2 · Cited by 62
Yang, Q., Lang, Y., Yang, W., Yang, F., Yang, J., Wu, Y., Xiao, X., Qin, C., Zou, Y., Zhao, Y., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110592 · Cited by 62
Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives
Rossing, P. R., Persson, F., & Frimodt‐Møller, M. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.02.007 · Cited by 62
Sloan, L. A. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12969 · Cited by 62
Information and consensus document for the detection and management of chronic kidney disease
Maset, R. G., Bover, J., Segura, J., Diezhandino, M. G., del Hoyo, J. C., Escalada, J., Fácila, L., Gamarra, J., García‐Donaire, J. A., Matarin, L. G., et al. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2022.07.003 · Cited by 61
Li, J., Albajrami, O., Zhuo, M., Hawley, C. E., & Paik, J. M. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02690320 · Cited by 61
Youth-Onset Type 2 Diabetes: Burden of Complications and Socioeconomic Cost
Marranzini-Rodriguez, I., & O’Sullivan, K. L. (2023) · Current Diabetes Reports · doi:10.1007/s11892-023-01501-7 · Cited by 60
Kitada, M., Ogura, Y., Monno, I., & Koya, D. (2018) · Nutrients · doi:10.3390/nu10050544 · Cited by 60
Klotho inhibits PKCα/p66SHC-mediated podocyte injury in diabetic nephropathy
Jiang, W., Xiao, T., Han, W., Xiong, J., He, T., Liu, Y., Huang, Y., Yang, K., Bi, X., Xu, X., et al. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110490 · Cited by 60
Lucey, M., Pickford, P., Bitsi, S., MINNION, J. S., Ungewiss, J., Schoeneberg, K., Rutter, G. A., Bloom, S. R., Tomás, A., & Jones, B. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.100991 · Cited by 60
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 60
Loh, H. H., Francis, B., Lim, Q. H., Lim, Q. H., Yee, A., & Loh, H. S. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3458 · Cited by 59
Hamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 59
Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024) · Obesity Reviews · doi:10.1111/obr.13717 · Cited by 58
Sachinidis, A. G., Nikolić, D., Stoian, A. P., Παπάνας, Ν., Tarar, O. H., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Mosterd, C. M., Bjornstad, P., & van Raalte, D. H. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00738-9 · Cited by 56
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials
Bailey, C. J., & Marx, N. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13492 · Cited by 56
Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.10.003 · Cited by 56
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13960 · Cited by 56
Caruso, I., & Giorgino, F. (2024) · Endocrine · doi:10.1007/s12020-024-03757-9 · Cited by 56
Liou, J.-H., Liu, Y.-M., & Chen, C. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.03.087 · Cited by 56
Drug repurposing in kidney disease
Panchapakesan, U., & Pollock, C. A. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.026 · Cited by 56
Chen, X., Huang, Q., Feng, J., Xiao, Z., Zhang, X., & Zhao, L. (2021) · Journal of International Medical Research · doi:10.1177/0300060521992981 · Cited by 55
Lin, Y., Wang, T.-H., Tsai, M., Wu, V. C., Tseng, C.-J., Lin, M., Li, Y., Chang, C., Chou, T., Tsai, T., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01793-9 · Cited by 55
Blonde, L., Belousova, L., Fainberg, U., Garcia‐Hernandez, P. A., Jain, S. M., Kaltoft, M. S., Mosenzon, O., Nafach, J., Palle, M. S., & Rea, R. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13978 · Cited by 54
Shubrook, J. H., Neumiller, J. J., & Wright, E. E. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.2009726 · Cited by 54
The Kidney in Obesity: Current Evidence, Perspectives and Controversies
Kounatidis, D. C., Vallianou, N. G., Stratigou, T., Voukali, M., Karampela, Ι., & Dalamaga, Μ. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00583-y · Cited by 54
Documento de abordaje integral de la diabetes tipo 2
Reyes‐García, R., Moreno, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Escalada, J., et al. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.10.010 · Cited by 54
Mouhayyar, C. E., Riachy, R., Khalil, A. B., Eid, A. A., & Azar, S. T. (2020) · International Journal of Endocrinology · doi:10.1155/2020/1762164 · Cited by 54
Stephens, J. W., Brown, K. E., & Min, T. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13942 · Cited by 54
Guedes, M. H., & Pecoits‐Filho, R. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13424 · Cited by 53
Mirabelli, M., CHIEFARI, E. D., Caroleo, P., Vero, R., Brunetti, F. S., Corigliano, D. M., Arcidiacono, B., FOTI, D. P., Puccio, L., & Brunetti, A. (2019) · Journal of Diabetes Research · doi:10.1155/2019/3971060 · Cited by 53
Dedov, I., Shestakova, M., Sukhareva, O., Mokrysheva, N., Andreeva, E., Bezlepkina, O., Peterkova, V., Artemova, E., Bardiugov, P., Bessmertnaya, E., et al. (2025) · Diabetes Mellitus · doi:10.14341/dm20255s · Cited by 53
Wang, M.-Y., Zhang, Z., Zhao, S., Onodera, T., Sun, X.-N., Zhu, Q., Li, C., Li, N., Chen, S., Paredes, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.024 · Cited by 52
Heinzel, A., Kammer, M., Mayer, G. J., Reindl‐Schwaighofer, R., Hu, K., Perco, P., Eder, S., Rosivall, L., Mark, P. B., Ju, W., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0532 · Cited by 52
The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus
Hussain, S. T., & Chowdhury, T. A. (2019) · Drugs · doi:10.1007/s40265-019-1061-4 · Cited by 52
Kammer, M., Heinzel, A., Willency, J. A., Duffin, K. L., Mayer, G. J., Simons, K., Gerl, M. J., Klose, C. D., Heinze, G., Reindl‐Schwaighofer, R., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.07.025 · Cited by 52
Folkerts, K., Petruski‐Ivleva, N., Kelly, A., Fried, L. F., Blankenburg, M., Gay, A., & Kovesdy, C. P. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.12.1506 · Cited by 52
Avilés, B., Soler, M. J., Perez-Belmonte, L. M., Jiménez-Millán, A., Rivas‐Ruiz, F., & de Lucas, M. D. G. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac096 · Cited by 51
Acute kidney injury in diabetes mellitus: Epidemiology, diagnostic, and therapeutic concepts
Gui, Y., Palanza, Z., Fu, H., & Zhou, D. F. (2023) · The FASEB Journal · doi:10.1096/fj.202201340rr · Cited by 51
Safety of liraglutide in type 2 diabetes and chronic kidney disease
Mann, J. F. E., Fonseca, V. A., Poulter, N. R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., Mosenzon, O., & on behalf of the LEADER Trial Investigators (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11881019 · Cited by 50
Self-citationXu, Y., Fu, E. L., Clase, C. M., Mazhar, F., Jardine, M., & Carrero, J. J. (2021) · Kidney International · doi:10.1016/j.kint.2021.10.033 · Cited by 50
Selvarajah, V., Robertson, D., Hansen, L., Jermutus, L., Smith, K., Coggi, A., Sánchez, J., Chang, Y.-T., Yu, H., Parkinson, J., et al. (2024) · Kidney International · doi:10.1016/j.kint.2024.08.023 · Cited by 49
Chronic Kidney Disease: Current State of the Problem
Батюшин, М. М. (2020) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2020-11-06 · Cited by 49
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., Bjornstad, P., Kramer, M. H. H., Diamant, M., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13223 · Cited by 49
Martin, W. P., White, J. P., López-Hernández, F. J., Docherty, N. G., & le Roux, C. W. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00289 · Cited by 49
GLP-1 Receptor: A New Target for Sepsis
Yang, F., Zeng, F., Luo, X., Lei, Y., Li, J., Lu, S., Huang, X., Lan, Y., & Liu, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.706908 · Cited by 48
Fernández‐Fernández, B., Fernández-Prado, R., Górriz, J. L., Martínez‐Castelao, A., Navarro‐González, J. F., Porrini, E., Soler, M. J., & Ortíz, A. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz070 · Cited by 48
Song, Y., Tan, Y., Deng, M., Shan, W., Zheng, W., Zhang, B., Cui, J., Feng, L., Shi, L., Zhang, M., et al. (2023) · MedComm · doi:10.1002/mco2.413 · Cited by 48
MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update
Cao, Q., Chen, X., Huang, C., & Pollock, C. A. (2019) · FASEB BioAdvances · doi:10.1096/fba.2018-00064 · Cited by 48
The future of new drugs for diabetes management
Bailey, C. J., & Day, C. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107785 · Cited by 48
Dejgaard, T. F., von Scholten, B. J., Christiansen, E., Kreiner, F. F., Bardtrum, L., von Herrath, M., Mathieu, C., Madsbad, S., & ADJUNCT ONE and ADJUNCT TWO Investigators (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14532 · Cited by 48
Agarwal, R., & Fouque, D. P. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac331 · Cited by 47
Krisanapan, P., Suppadungsuk, S., Sanpawithayakul, K., Thongprayoon, C., Pattharanitima, P., Tangpanithandee, S., Mao, M. A., Miao, J., & Cheungpasitporn, W. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae018 · Cited by 47
Management of type 2 diabetes in chronic kidney disease
Triozzi, J. L., Gregg, L. P., Virani, S. S., & Navaneethan, S. D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002300 · Cited by 47
Melson, E., Miras, A. D., & Papamargaritis, D. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0144 · Cited by 46
Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota
Ni, Y., Zheng, L., Nan, S., Ke, L., Fu, Z., & Jin, J. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022140 · Cited by 46
Rodriguez‐Valadez, J. M., Tahsin, M., Fleischmann, K. E., Masharani, U. B., Yeboah, J., Park, M., Li, L., Weber, E. S., Li, Y., Berkalieva, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-0772 · Cited by 46
Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes
Terenzi, D. C., Al-Omran, M. A., Quan, A., Teoh, H., Verma, S., & Hess, D. A. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.10.005 · Cited by 46
Kawai, Y., Uneda, K., Yamada, T., Kinguchi, S., Kobayashi, K., Azushima, K., Kanaoka, T., Toya, Y., Wakui, H., & Tamura, K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109146 · Cited by 46
The role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
Furth, S. L., Colhoun, H. M., Kanbay, M., Kukla, A., Lim, L., MacLaughlin, H. L., Navaneethan, S. D., Shroff, R. C., Stenvinkel, P., Cheung, M., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.09.019 · Cited by 45
Self-citationThe Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Yin, W. L., Bain, S. C., & Min, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00798-x · Cited by 45
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 45
Diabetes, Albuminuria and the Kidney—Brain Axis
Smera, D. M. A., Jiménez-Baladó, J., Maisterra, O., Pujadas, F., Soler, M. J., & Delgado, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112364 · Cited by 44
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 44
Lo, C., Jun, M., Badve, S. V., Pilmore, H., White, S. L., Hawley, C. M., Cass, A., Perkovic, V., & Zoungas, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub2 · Cited by 44
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease
Hanrahan, J. P., de Boer, I. H., Bakris, G. L., Wilson, P. J., WAKEFIELD, J. D., Seferović, J. P., Chickering, J. G., Chien, Y., Carlson, K. E., Cressman, M. D., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08410520 · Cited by 44
MicroRNAs and their delivery in diabetic fibrosis
Wonnacott, A., Denby, L., Coward, R. J., Fraser, D. J., & Bowen, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114045 · Cited by 44
Xu, X., Eales, J., Jiang, X., Sanderson, E. C. M., Drzal, M., Saluja, S., Scannali, D., Williams, B., Morris, A. P., Guzik, T. J., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab357 · Cited by 44
Fadini, G. P., Sarangdhar, M., & Avogaro, A. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000475 · Cited by 44
Gorenek, B., Boriani, G., Dan, G.-A., Fauchier, L., Fenelon, G., Huang, H., Kudaiberdieva, G., Lip, G. Y. H., Mahajan, R., Potpara, T., et al. (2018) · EP Europace · doi:10.1093/europace/euy051 · Cited by 43
Hu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43
Najafi, S., Bahrami, M., Butler, A. E., & Sahebkar, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15344 · Cited by 43
Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases
Yang, F., Luo, X., Li, J., Yu, L., Zeng, F., Huang, X., Lan, Y., & Liu, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113236 · Cited by 43
Mima, A., Gotoda, H., Lee, R., Murakami, A., Akai, R., & Lee, S. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100236 · Cited by 43
Slowing the Progression of Diabetic Kidney Disease
Blazek, O., & Bakris, G. L. (2023) · Cells · doi:10.3390/cells12151975 · Cited by 43
Movahednasab, M., Dianat‐Moghadam, H., Khodadad, S., Nedaeinia, R., Safabakhsh, S., Ferns, G. A., & Salehi, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01623-w · Cited by 43
Trevisan, M., Fu, E. L., Szummer, K. E., Norhammar, A., Lundman, P., Wanner, C., Sjölander, A., Jernberg, T., & Carrero, J. J. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa004 · Cited by 43
Tuttle, K. R., Rayner, B., Lakshmanan, M. C., Kwan, A. Y. M., Konig, M., Shurzinske, L., & Botros, F. T. (2021) · Kidney360 · doi:10.34067/kid.0005852020 · Cited by 42
Frías, J. P., Choi, J., Rosenstock, J., Popescu, L., Niemoeller, E., Muehlen-Bartmer, I., & Baek, S. J. (2022) · Diabetes Care · doi:10.2337/dc21-2656 · Cited by 42
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 42
Obesity and Weight Loss Strategies for Patients With Heart Failure
Vest, A. R., Schauer, P. R., Rodgers, J. E., Sanderson, E., LaChute, C., Seltz, J., Lavie, C. J., Mandras, S. A., Tang, W. H. W., & daSilva‐deAbreu, A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.06.006 · Cited by 42
Liakos, A., Lambadiari, V., Bargiota, Α., Kitsios, K., Avramidis, I., Kotsa, K., Gerou, S., Boura, P., Tentolouris, N., Dimitriadis, G., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13541 · Cited by 42
Preventing and treating kidney disease in patients with type 2 diabetes
Delanaye, P., & Scheen, A. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1551362 · Cited by 42
Management of diabetes mellitus in chronic kidney disease
Garla, V. V., Kanduri, S. R., Yanes-Cardozo, L. L., & Lien, L. F. (2019) · Minerva Endocrinology · doi:10.23736/s0391-1977.19.03015-3 · Cited by 42
Lee, C.-L., Chen, C., Wu, M., & Tsai, S. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319898370 · Cited by 42
von Scholten, B. J., Kreiner, F. F., Rasmussen, S., Rossing, P. R., & Idorn, T. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221112490 · Cited by 41
Self-citationBeyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Guglielmi, V., Bettini, S., Sbraccia, P., Busetto, L., Pellegrini, M., Yumuk, V., Colao, A. M. L., Ghoch, M. E., & Muscogiuri, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00502-7 · Cited by 41
ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases
Ikizler, T. A., Kramer, H., Beddhu, S., Chang, A. R., Friedman, A. N., Harhay, M. N., Jimenez, E. Y., Kistler, B. M., Kukla, A., Larson, K., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000512 · Cited by 41
Xu-bin, W., Wei, W., Ding, L., & Liu, S.-Y. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.08.017 · Cited by 41
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Lassen, M. C. H., Johansen, N. D., Modin, D., Catarig, A., Vistisen, B. K., Amadid, H., Zimmermann, E., Gislason, G., & Biering‐Sørensen, T. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15872 · Cited by 40
Clemens, K. K., Ernst, J., Khan, T., Reichert, S., Khan, M. Q., LaPier, H., Chiu, M., Stranges, S., Sahi, G., Castrillon-Ramirez, F., et al. (2023) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.023 · Cited by 40
Metadata
- Authors
- Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B.
- Affiliations
- Mount Sinai Hospital (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-31
- Volume
- 377
- Issue
- 9
- Pages
- 839-848
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752707491
- Semantic Scholar
- e3932087f500b455476965939bdced15360eb028
- Cited by
- 1,253
- References
- 32
- Citations by year
- 2026: 99 · 2025: 116 · 2024: 121 · 2023: 131 · 2022: 134 · 2021: 161 · 2020: 180 · 2019: 139 · 2018: 152 · 2017: 20
- FWCI
- 106.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- ResearchOnline - JCU (James Cook University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- Novo Nordisk
- National Institutes of Health (UL1TR001111)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- liraglutide, type 2 diabetes, renal outcomes, diabetic nephropathy, macroalbuminuria, end-stage renal disease, acute kidney injury, glucagon-like peptide-1 analogues, albuminuria, estimated glomerular filtration rate, cardiovascular risk, renal adverse effects, LEADER trial, cardiovascular outcomes, serum creatinine doubling, usual care
- MeSH terms
- Liraglutide, Aged, Albuminuria, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Kidney Failure, Chronic, Male, Middle Aged, Glucagon-Like Peptide 1, Intention to Treat Analysis, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
